(Reuters) -Medical device maker Insulet on Thursday posted third-quarter results that surpassed Wall Street’s expectations on strong demand for its wearable insulin pumps, which eliminate the need for daily injections.

Insulet’s sales have risen since the broader approval for its automated insulin delivery device, Omnipod, that can be attached to the skin.

Its Omnipod 5 device was cleared in the U.S. for patients with type 2 diabetes last year, two years after approval for type 1 diabetes patients.

In September, Insulet appointed industry veteran Flavia Pease as the finance chief and said it expects third-quarter revenue to exceed prior forecasts.

Insulet’s larger peer, Dexcom, also reported robust demand for its continuous glucose monitoring systems.

Insulet now expects annual revenu

See Full Page